{"id":"W4387811241","doi":"10.1016/j.annonc.2023.09.2158","title":"1019O Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Chugai Pharmaceutical; Astellas Pharma; Eisai; Daiichi-Sankyo; Svenska Forskningsrådet Formas; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; BeiGene; Pfizer; INOVIO Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Nivolumab; Internal medicine; Neutropenia; Oncology; CD8; Pembrolizumab; Cytokine release syndrome; Melanoma; Immunotherapy; Immunology; Antigen; Chimeric antigen receptor; Chemotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162293,0.0006176941,0.0009199691,0.0001996069,0.0004325754,0.001208825,0.0003180126,0.0006789477,0.01109532],"category_scores_gemma":[0.000725974,0.0002007454,0.0007113747,0.0002679969,0.0004608096,0.0006565696,0.0002782932,0.002108588,0.002113408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007628153,"about_ca_system_score_gemma":0.0008695319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001130437,"about_ca_topic_score_gemma":0.004094442,"domain_scores_codex":[0.9996452,0.0001332666,0.00002264568,0.00005195,0.00005899734,0.00008793714],"domain_scores_gemma":[0.9994783,0.0001347597,0.00005742476,0.00005270165,0.00005464672,0.0002221071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3592991,0.02112695,0.01238397,0.001443505,0.002538322,0.0003983128,0.0002057249,0.002623213,0.09744065,0.001684903,0.04197716,0.4588781],"study_design_scores_gemma":[0.2767372,0.3987102,0.08075,0.0003064059,0.003133325,0.001649479,0.0003904214,0.003596108,0.0470653,0.002512309,0.1850349,0.0001144853],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9354749,0.01188005,0.001331738,0.005290745,0.0009737361,0.001286924,0.009491091,0.0002118282,0.03405894],"genre_scores_gemma":[0.9541185,0.005102811,0.002215976,0.003938648,0.0004238381,0.0007577798,0.01672582,0.00009161518,0.01662508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01109532,"threshold_uncertainty_score":0.03711754,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3242130588186991,"score_gpt":0.5044721720448572,"score_spread":0.1802591132261581,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}